Top

International Journal of Clinical Oncology

Published in:

01-08-2013 | Original Article

Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients

Authors: Seiya Saito, Naoko Hayashi, Nobutaka Sato, Masaaki Iwatsuki, Yoshifumi Baba, Yasuo Sakamoto, Yuji Miyamoto, Masayuki Watanabe, Minoru Yoshida, Kenji Sakai, Takashi Katsumori, Shigeru Katahuchi, Nobuyuki Shigaki, Kazutaka Yamada, Masami Kimura, Tomio Tanigawa, Sadamu Takano, Masafumi Kuramoto, Hideo Baba

Published in: International Journal of Clinical Oncology | Issue 4/2013

Abstract

Background

There has so far been little information on the clinical effect of bevacizumab against colorectal cancer in Japan. Hence, this study was conducted to retrospectively evaluate the safety and efficacy of bevacizumab in clinical practice.

Methods

A total of 181 patients with metastatic colorectal cancer (mCRC) received bevacizumab in combination with chemotherapy at 18 hospitals in Kumamoto prefecture, Japan. We surveyed the medical records of all patients regarding the patient characteristics, objective tumor responses, and adverse events. We analyzed their overall survival and the survival benefit when continuing the administration of bevacizumab beyond disease progression (progressive disease; PD) in patients who received bevacizumab-containing 1st line therapy.

Results

The response rate (RR) in all lines of therapy was 42 %. The 1st line patients showed significantly better survival in comparison to the patients who received further lines of treatment (P = 0.005). There were no significant differences in survival between the group with post-PD treatment with bevacizumab and the group with post-PD treatment without bevacizumab (P = 0.13). The most common grade 3 or greater adverse event associated with bevacizumab was hypertension (12.2 %). Especially, a high incidence of gastrointestinal (GI) perforation was shown in this study (4.4 %) and most of the patients with GI perforation had some risk factors for this complication.

Conclusion

Although the survival benefit of bevacizumab in Japanese patients with mCRC was similar to that observed in previous clinical trials, this study showed a high incidence of GI perforation in comparison to previous studies. Therefore, the careful selection of patients with few risk factors for this complication is likely to lead to a greater benefit from bevacizumab treatment.

Kotake K, Honjo S, Sugihara K et al (2003) Changes in colorectal cancer during a 20-year period: an extended report from the multi-institutional registry of large bowel cancer, Japan. Dis Colon Rectum 46(10 Suppl):S32–S43PubMed

Muto T, Kotake K, Koyama Y (2001) Colorectal cancer statistics in Japan: data from JSCCR registration, 1974–1993. Int J Clin Oncol 6(4):171–176PubMedCrossRef

Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–1186PubMedCrossRef

Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(6 Suppl 16):15–18PubMed

Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77(7):527–543PubMedCrossRef

Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145–147PubMedCrossRef

Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7(9):987–989PubMedCrossRef

Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef

Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019PubMedCrossRef

10.

Doi T, Boku N, Kato K et al. (2010) Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 40(10):913–920

11.

Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21(1):60–65PubMedCrossRef

12.

Tamiya A, Yamazaki K, Boku N et al (2009) Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol 14(6):513–517PubMedCrossRef

13.

Van Cutsem E, Rivera F, Berry S et al (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 20(11):1842–1847PubMedCrossRef

14.

Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349(5):427–434PubMedCrossRef

15.

Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25(12):1539–1544PubMedCrossRef

16.

Kabbinavar FF, Schulz J, McCleod M et al (2005) Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23(16):3697–3705PubMedCrossRef

17.

Grothey A, Sugrue MM, Purdie DM et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326–5334PubMedCrossRef

18.

Van Cutsem E, M Michael, S Berry (2007) Preliminary safety and efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI, and capecitabine for mCRC: first-BEAT trial. Gastrointestinal Cancer Symposium (abstract #346)

19.

Flynn P, MM Sugrue, DM Purdie (2008) Serious bleeding events are umcommon in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab (BV) as part of a first-line regimen: results from the BRiTE observational Cohort Study. Gastrointestinal Cancer Symposium (abstract #346)

20.

Kozloff M, J Hainsworth, S Badarinath (2007) Management of hypertension (HTN) in patients (pts) with metastatic colorectal cancer treated with bevacizumab (BV) plus chemotherapy. Gastrointestinal Cancer Symposium (abstract #364)

21.

Sugrue MM, M Kozloff, J Hainsworth (2007) Safety and effectiveness of bevacizumab plus chemotherapy in elderly patients with mCRC: result from the BRiTE registry. Gastrointestinal Cancer Symposium (abstract #345)

22.

Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10(6):559–568PubMedCrossRef

23.

Hedrick E, M Kozloff, J Hainsworth (2006) Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US(BRiTE). ASCO Annual Meeting (abstract #3536), Atlanta, USA

24.

Saif MW, Elfiky A, Salem RR (2007) Gastrointestinal perforation due to bevacizumab in colorectal cancer. Ann Surg Oncol 14(6):1860–1869PubMedCrossRef

25.

Han ES, Monk BJ (2007) What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? Gynecol Oncol 105(1):3–6PubMedCrossRef

Title: Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients
Authors: Seiya Saito
Naoko Hayashi
Nobutaka Sato
Masaaki Iwatsuki
Yoshifumi Baba
Yasuo Sakamoto
Yuji Miyamoto
Masayuki Watanabe
Minoru Yoshida
Kenji Sakai
Takashi Katsumori
Shigeru Katahuchi
Nobuyuki Shigaki
Kazutaka Yamada
Masami Kimura
Tomio Tanigawa
Sadamu Takano
Masafumi Kuramoto
Hideo Baba
Publication date: 01-08-2013
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 4/2013
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-012-0426-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2013

Reduced-dose docetaxel for castration-resistant prostate cancer has no inferior impact on overall survival in Japanese patients

Prognostic scoring system for stage IV colorectal cancer: is the AJCC sub-classification of stage IV colorectal cancer appropriate?

Role of CD44 expression in non-tumor tissue on intrahepatic recurrence of hepatocellular carcinoma

Low microvascular density at the tumor center is related to the expression of metalloproteases and their inhibitors and with the occurrence of distant metastasis in breast carcinomas

Recent advances in reconstructive surgery

Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer